Life-threatening risks from weight-loss injections – an overview
The so-called "weight loss injections" based on GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide; trade names such as Ozempic, Wegovy, Mounjaro) have become established in obesity and diabetes therapy – but serious, sometimes life-threatening side effects are increasingly being reported. Gastrointestinal catastrophes Among the most serious complications are acute inflammation of the pancreas (pancreatitis), intestinal obstruction (ileus), and gastric paresis (gastroparesis). In addition to nausea, vomiting, and diarrhea, individual patients can rapidly develop life-threatening conditions. Current studies show that the risk of pancreatitis under GLP-1 agonists can be up to 9 times higher compared to other weight loss preparations. A few deaths attributed to multiple organ failure after pancreatitis have already been documented[1][2][3][4]. Mechanical intestinal obstruction also occurred with clinically noticeable frequency: Ileus can develop due to the slowed gastrointestinal passage under the medication, with the risk of rupture (perforation) and circulatory shock[2][3]. The result is emergencies requiring immediate inpatient treatment and surgical...







